

3-(4-Dihydroxyborylphenyl)cyclobutanone

Jem-Mau Lo,^a Shyh-Ming Chen,^b
Mei-Hsun Chen,^a Yu-Jen Chen,^a
Fen-Ling Liao^c and
Tian-Huey Lu^{d*}^aDepartment of Nuclear Science, National Tsing Hua University, Hsinchu 300, Taiwan,^bComputer and Communication Center, National Tsing Hua University, Hsinchu 300, Taiwan, ^cDepartment of Chemistry, National Tsing Hua University, Hsinchu 300, Taiwan, and ^dDepartment of Physics, National Tsing Hua University, Hsinchu 300, Taiwan

Correspondence e-mail: thlu@phys.nthu.edu.tw

Key indicators

Single-crystal X-ray study

T = 294 K

Mean $\sigma(\text{C}-\text{C}) = 0.002 \text{ \AA}$

R factor = 0.034

wR factor = 0.102


Data-to-parameter ratio = 11.2

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

The title compound, $\text{C}_{10}\text{H}_{11}\text{BO}_3$, may be developed as a potent boron neutron capture therapy (BNCT) drug for hepatoma treatment. The compound was obtained as transparent rectangular plate crystals. Intermolecular hydrogen bonds and $\pi-\pi$ interactions help stabilize the crystal structure.

Comment

Hepatoma is one of the most prevalent malignant tumors occurring in Taiwan. Because the symptoms of hepatoma are not obvious and most patients would incur cirrhosis at the same time, it is difficult to treat hepatoma by surgical resection. Hepatoma treatment is also not very effective by means of chemical therapy or radiation therapy; boron neutron capture therapy (BNCT) has been recently considered as an alternative useful method for treating hepatoma (Aris *et al.*, 2004). The title compound, (I), has recently been developed in our laboratory as a potent BNCT agent for hepatoma treatment (Lo *et al.*, 2003). The compound has been successfully synthesized and grown as crystals. The crystal structure is reported here.



There exist two strong $[\text{O}1-\text{H}1\text{O}\cdots\text{O}2(2-x, -y, -z)]$ and $[\text{O}2-\text{H}2\text{O}\cdots\text{O}1(2-x, \frac{1}{2}+y, \frac{1}{2}-z)]$ hydrogen bonds and one weak $[\text{C}10-\text{H}10\text{B}\cdots\text{O}3(x, -\frac{1}{2}-y, z-\frac{1}{2})]$ hydrogen bond, with bond lengths (and angles) of 2.834 (3) \AA [166 (2) $^\circ$], 3.039 (4) \AA [160 (3) $^\circ$] and 3.447 (4) \AA [166 (3) $^\circ$], respectively. In addition to the intermolecular hydrogen bonds, the crystal packing involves intermolecular $\pi-\pi$ interactions, mainly between cyclobutanone rings, $(1-x, -y, -z)$, with a distance of 4.267 (4) \AA , between benzene rings, $(-x, -y, 1-z)$, with a distance of 4.770 (4) \AA , and between the benzene ring and the cyclobutanone ring at $(1-x, -y, 1-z)$, with a distance of 4.874 (4) \AA . The benzene ring has a maximum deviation of

Received 18 August 2004

Accepted 9 September 2004

Online 25 September 2004

Contribution No. BTO6.




Figure 1
The molecular structure of the title compound, showing 30% probability displacement ellipsoids.

0.0047 (10) Å from its least-squares plane. The maximum deviation from the mean plane of the four-membered cyclobutanone ring is 0.0423 (9) Å. The benzene ring is almost perpendicular [86.71 (7)°] to the cyclobutanone ring and is coplanar [7.43 (9)°] with the plane formed by atoms C1, O1 and O2.

The B—C1 distance of 1.558 (2) Å is in good agreement with comparable phenylboronic acids where values range from 1.526 Å in *p*-bromophenylboronic acid (Zvonkova & Gluskova, 1958) to 1.597 Å in 6-bis(trifluoromethyl)phenyldihydroxyborane (Cornet *et al.*, 2003). B—O1 [1.364 (2) Å] and B—O2 [1.371 (2) Å] lie at the upper end of the corresponding range, viz. 1.323 Å in (*O,O'*)-[hydroxy[4-(dihydroxyboryl)phenyl]boron] bis(dimethylglyoximate)aquamethylcobalt trihydrate (Dreos *et al.*, 2003) to 1.376 Å in *L-p*-boronophenylalanine (Shull *et al.*, 2000). The situation is different in cyclo-tris[bis(pentafluorophenyl)borinic acid] (Beringhelli *et al.*, 2003), where steric crowding by the six pentafluorophenyl ligands results in much longer B—O distances, ranging from 1.519 to 1.535 Å.

Experimental

The precursor for synthesizing the title compound, 3-(4-boronophenyl)cyclobutanone ethylene ketal, was obtained by a previously reported process (Fu, 2002; Srivastava *et al.*, 1999). A 100 ml round-bottomed flask was charged with 3-(4-dihydroxyborylphenyl)cyclobutanone ethylene ketal (5.8 mmol, 1.36 g) in methanol (14 ml), along with concentrated hydrochloric acid (10 drops). The contents of the flask were stirred overnight at room temperature, and then the solvent was removed under reduced pressure by a rotary evaporator. The residue was dissolved in diethyl ether and washed with water and




Figure 2
The two-dimensional hydrogen-bonding network (dashed lines) of the title compound.

then brine. The organic layer was collected and dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The product was purified using silica gel chromatography (20 × 2 cm, 20 and 40% ethyl acetate in hexane) to obtain the final product as a white solid (0.46 g, 33.8% yield): *R_f* = 0.46 (50% ethyl acetate in hexane, silica gel TLC). For recrystallization, the white solid was dissolved in diethyl ether to form a near saturated solution, which was filtered through a filter paper. The resulting clear filtrate was poured into a glass column bottle, covered with a filter paper and kept in a refrigerator at 268 K for 24 h, allowing the solvent to evaporate gradually. With the remaining 3 ml of solution, the bottle was moved from the refrigerator and kept at room temperature to expedite the evaporation. Rectangular crystals formed after some time and suitable crystals were harvested for X-ray structure analysis. M.p. 367–371 K. ¹H NMR (CDCl₃): δ 7.71 (*d*, *J* = 7.3 Hz, 2H), 7.32 (*d*, *J* = 7.3 Hz, 2H), 3.64 (*m*, 1H), 3.47 (*m*, 2H), 3.22 (*m*, 2H). ¹³C NMR (CDCl₃): δ 206.38, 148.13, 135.64, 126.24, 54.43, 28.56.

Crystal data

C₁₀H₁₁BO₃
M_r = 190.00
Monoclinic, *P*2₁/*c*
a = 11.4645 (11) Å
b = 9.8317 (9) Å
c = 8.3674 (8) Å
β = 98.551 (2)°
V = 932.65 (15) Å³
Z = 4

D_x = 1.353 Mg m⁻³
Mo Kα radiation
Cell parameters from 5680 reflections
θ = 2.0–28.0°
μ = 0.10 mm⁻¹
T = 294 (2) K
Rectangular plate, colourless
0.15 × 0.10 × 0.05 mm

Data collection

Bruker SMART CCD area-detector diffractometer
φ and ω scans
Absorption correction: multi-scan (SHELXTL; Bruker, 2000)
T_{min} = 0.927, *T_{max}* = 0.993
5481 measured reflections

1915 independent reflections
1198 reflections with *I* > 2σ(*I*)
R_{int} = 0.076
θ_{max} = 26.4°
h = -14 → 12
k = -11 → 12
l = -10 → 10

Refinement

Refinement on *F*²
R[*F*² > 2σ(*F*²)] = 0.034
wR(*F*²) = 0.102
S = 0.96
1915 reflections
171 parameters

All H-atom parameters refined
w = 1/[σ²(*F_o*²)(0.1*P*)²]
where *P* = (*F_o*² + 2*F_c*²)/3
(Δσ)_{max} < 0.001
Δρ_{max} = 0.15 e Å⁻³
Δρ_{min} = -0.13 e Å⁻³

Table 1

Selected geometric parameters (Å, °).

O1–B	1.364 (2)	O3–C9	1.200 (2)
O2–B	1.371 (2)	C1–B	1.558 (2)
C2–C1–B	122.9 (1)	O1–B–O2	117.1 (1)
C6–C1–B	120.8 (1)	O1–B–C1	119.1 (1)
O3–C9–C10	134.0 (2)	O2–B–C1	123.8 (1)
O3–C9–C8	132.8 (2)		

H atoms were located in a difference Fourier synthesis and refined isotropically [C–H = 0.924 (17)–1.009 (19) Å].

Data collection: *SMART* (Bruker, 1998); cell refinement: *SAINTE* (Bruker, 2000); data reduction: *SAINTE*; program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEP-3 for Windows* (Farrugia, 1997); software used to prepare material for publication: *SHELXL97*.

The authors thank the National Science Council, Republic of China, for support under grant Nos. NSC 92-2745-P-075-001, and the Veterans General Hospitals University System of

Taiwan Joint Research Program, Tsou's Foundation, for support under grant No. VGHUST 93-G2-02.

References

- Aris, Z., Tazio, P., Ubaldo, P., Francesca, F., Saverio, A. & Laura, R. (2004). BNCT Pavia Project, University of Pavia, Italy.
- Beringhelli, T., D'Alfonso, G., Donghi, D., Maggioni, D., Mercandelli, P. & Sironi, A. (2003). *Organometallics*, **22**, 1588–1590.
- Bruker (1998). *SMART*. Version 5.054. Bruker AXS Inc., Madison, Wisconsin, USA.
- Bruker (2000). *SHELXTL* (Version 6.1) and *SAINTE* (Version 6.02a). Bruker AXS Inc., Madison, Wisconsin, USA.
- Cornet, S. M., Dillon, K. B., Entwistle, C. D., Fox, M. A., Goeta, A. E., Goodwin, H. P., Marder, T. B. & Thompson, A. L. (2003). *Dalton Trans.* pp. 4395–4405.
- Dreos, R., Nardin, G., Randaccio, L., Siega, P. & Tazher, G. (2003). *Inorg. Chem.* **42**, 612–614.
- Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.
- Fu, I. Y. (2002). MS thesis, National Tsing Hua University, Taiwan.
- Lo, J. M., Wu, P. Y., Fu, I. Y. & Cheng, H. W. (2003). *J. Nucl. Med.* **44**, 309.
- Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
- Shull, B. K., Spielvogel, D. E., Gopaldaswamy, R., Sankar, S., Boyle, P. D., Head, G. & Devito, K. (2000). *J. Chem. Soc. Perkin Trans. 2*, 557–559.
- Srivastava, R. R., Singhaus, R. R. & Kaballa, G. W. (1999). *J. Org. Chem.* **64**, 8495–8500.
- Zvonkova, Z. V. & Gluskova, V. P. (1958). *Kristallografiya* (in Russian) (*Crystallogr. Rep.*), **3**, 559–562.